Filtered By:
Specialty: Biotechnology
Therapy: Chemotherapy

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 20 results found since Jan 2013.

Efficient in vitro gene therapy with PEG siRNA lipid nanocapsules for passive targeting strategy in melanoma.
The objective of this work consists in formulating and optimizing the encapsulation of siRNA into lipid nanocapsules (LNCs) for efficient gene therapy on melanoma cells. SiRNA LNCs were prepared from DOTAP/DOPE lipoplexes, and the siRNA dose and lipid/siRNA charge ratio were assayed to improve the stability and encapsulation yield. Cryo-TEM imaging of the siRNA lipoplexes and LNC morphology revealed a specific organization of the siRNA DOTAP/DOPE lipoplexes as well as specific lipid microstructures. No cytotoxicity of the siRNA LNCs against the melanoma SK-Mel28 cell line was observed at concentrations of up to 500 ng/mL s...
Source: Biotechnology Journal - September 26, 2014 Category: Biotechnology Authors: Resnier P, LeQuinio P, Lautram N, André E, Gaillard C, Bastiat G, Benoit JP, Passirani C Tags: Biotechnol J Source Type: research

Recent advances in mechanism-based chemotherapy drug-siRNA pairs in co-delivery systems for cancer: A review.
Abstract Co-delivery of chemotherapy drugs and siRNA for cancer therapy has achieved remarkable results according to synergistic/combined antitumor effects, and is recognized as a promising therapeutic modality. However, little attention has been paid to the extremely complex mechanisms of chemotherapy drug-siRNA pairs during co-delivery process. Proper selection of chemotherapy drug-siRNA pairs is beneficial for achieving desirable cancer therapeutic effects. Exploring the inherent principles during chemotherapy drug-siRNA pair selection for co-delivery would greatly enhanced therapeutic efficiency. To achieve id...
Source: Colloids and Surfaces - June 8, 2017 Category: Biotechnology Authors: Wang M, Wang J, Li B, Meng L, Tian Z Tags: Colloids Surf B Biointerfaces Source Type: research

Co-delivery of doxorubicin and siRNA by a simplified platform with oligodeoxynucleotides as a drug carrier.
In this study, a simplified and effective system for the co-loading and intracellular co-delivery of doxorubicin (Dox) and siRNA was developed. Oligodeoxynucleotides with CGA repeating units (CGA-ODNs) were introduced to load Dox. The loading mechanism was based on the ability of Dox to intercalate within double-stranded 5'-GC-3' or 5'-CG-3' sequences. Poly(ethyleneimine) (PEI) was used to condense siRNA and Dox loaded CGA-ODNs (CGA-ODNs-Dox) to obtain Dox and siRNA co-loaded nanocomplexes (PEI/CGA-ODNs-Dox&siRNA, PDR). The cellular uptake of PDR in A549 and HepG2 cells was 39.52% and 36.78%, respectively, indicating t...
Source: Colloids and Surfaces - January 14, 2015 Category: Biotechnology Authors: Liu T, Wang M, Wang T, Yao Y, Zhang N Tags: Colloids Surf B Biointerfaces Source Type: research

Phenylboronic acid-functionalized polyamidoamine-mediated Bcl-2 siRNA delivery for inhibiting the cell proliferation.
In conclusion, the PPP-mediated Bcl-2 siRNA delivery could potentially be an effective platform for solving the drug resistance and further achieving the combined chemotherapy and gene therapy in tumor treatment. PMID: 27371891 [PubMed - as supplied by publisher]
Source: Colloids and Surfaces - June 19, 2016 Category: Biotechnology Authors: Wu D, Yang J, Xing Z, Han H, Wang T, Zhang A, Yang Y, Li Q Tags: Colloids Surf B Biointerfaces Source Type: research

Near-infrared light-activatable siRNA delivery by microcapsules for combined tumour therapy.
Authors: Rui Y, Pang B, Zhang J, Liu Y, Hu H, Liu Z, Ama Baidoo S, Liu C, Zhao Y, Li S Abstract A polyelectrolyte microcapsule-based layer-by-layer (LbL) technique has been widely used as a multifunctional vehicle for combined tumor therapy. Meanwhile, with the rapid development of combined tumour therapy, the challenge for designing multifunctional drug delivery system has attracted much more attention. Herein, we developed a new type of microcapsule (MC) system called MPA@siRNA@DOX@MC, which conjugated with siRNA and DOX as well as ICG-Der-02 (MPA) by electrostatic absorption. MPA as indocyanine green (ICG) fluor...
Source: Artificial Cells, Nanomedicine and Biotechnology - March 14, 2018 Category: Biotechnology Tags: Artif Cells Nanomed Biotechnol Source Type: research

Aptamer-conjugated nanoliposomes containing COL1A1 siRNA sensitize CRC cells to conventional chemotherapeutic drugs
In this study, As1411 aptamer-conjugated liposomes were used for targeted siRNA delivery against the COL1A1 gene in colorectal cancer (CRC) cells. Cationic liposomes were synthesized and siRNA loading and conjugation of aptamer were confirmed by gel shift assay and spectrophotometry method. Release of siRNA from liposomes was assessed using dialysis method. Binding and uptake of aptamer-conjugated liposomes to and into cancer cells was assessed by fluorescence microscopy and flowcytometry. Gene expression was evaluated using qRT-PCR. Cell viability, chemosensitivity and apoptosis were determined by MTT assay and Annexin/PI...
Source: Colloids and Surfaces - July 29, 2022 Category: Biotechnology Authors: Hamed Manoochehri Akram Jalali Hamid Tanzadehpanah Amir Taherkhani Rezvan Najafi Source Type: research

The impact of the codelivery of drug-siRNA by trimethyl chitosan nanoparticles on the efficacy of chemotherapy for metastatic breast cancer cell line (MDA-MB-231).
Authors: Eivazy P, Atyabi F, Jadidi-Niaragh F, Aghebati Maleki L, Miahipour A, Abdolalizadeh J, Yousefi M Abstract High-mobility group protein two (HMGA2), a nonhistone nuclear-binding protein and its downregulators; vimentin, matrix metallopeptidase-9 (MMP-9), and E-cadherin are shown to contribute to tumor progression and metastasis. Thus, in this study, we checked simultaneous delivery of HMGA-2 siRNA and the anticancer drug doxorubicin to enhance the anticancer treatment effects. For this purpose, we used MTT assay and real-time polymerase chain reaction (RT-PCR). Our results showed that dual delivery of Dox an...
Source: Artificial Cells, Nanomedicine and Biotechnology - May 19, 2016 Category: Biotechnology Tags: Artif Cells Nanomed Biotechnol Source Type: research

Recent advances in siRNA delivery systems for prostate cancer therapy
Curr Pharm Biotechnol. 2021 Jun 15. doi: 10.2174/1389201022666210615123211. Online ahead of print.ABSTRACTThe critical problems of conventional prostate cancer therapeutic strategies like nonspecific toxicity and multi-drug resistance prompted the development and application of countless nanoparticle-based siRNA therapeutics. The main challenges to siRNA-based therapeutics becoming a new paradigm in the treatment of prostate cancer stem from the lack of safe and effective delivery systems, immune system stimulation, poor knowledge of nano-bio interactions, and limitations concerning designing, manufacturing, clinical trans...
Source: Current Pharmaceutical Biotechnology - June 16, 2021 Category: Biotechnology Authors: Shahin Aghamiri Pourya Raee Shiva Shahmohamadnejad Sasan Shabani Jaber Ghorbani Marzieh Sameni Mohammad Taha Ebrahimi Source Type: research

Nano Carriers That Enable Co-Delivery of Chemotherapy and RNAi Agents for Treatment of Drug-Resistant Cancers.
Abstract Tumor cells exhibit drug resistant phenotypes that decrease the efficacy of chemotherapeutic treatments. The drug resistance has a genetic basis that is caused by an abnormal gene expression. There are several types of drug resistance: efflux pumps reducing the cellular concentration of the drug, alterations in membrane lipids that reduce cellular uptake, increased or altered drug targets, metabolic alteration of the drug, inhibition of apoptosis, repair of the damaged DNA, and alteration of the cell cycle checkpoints (Gottesman et al. , 2002, Holohan et al. , 2013). siRNA is used to silence the drug resi...
Source: Biotechnology Advances - June 9, 2014 Category: Biotechnology Authors: Tsouris V, Joo MK, Kim SH, Kwon IC, Won YY Tags: Biotechnol Adv Source Type: research

Novel nanocarriers for silencing anti-phagocytosis CD47 marker in acute myeloid leukemia cells
Colloids Surf B Biointerfaces. 2022 Jun 1;217:112609. doi: 10.1016/j.colsurfb.2022.112609. Online ahead of print.ABSTRACTAcute myeloid leukemia (AML), a malignant disorder of Hematopoietic stem cells, can escape immunosurveillance by over expression of the cluster of differentiation 47 (CD47) marker, which functions as an inhibitory signal, suppressing phagocytosis by binding to signal regulatory protein α (SIRPα) on macrophages. AML is treated mainly by chemotherapy, which has drastic side effects and poor outcomes for the patients. Most AML patients develop drug resistance, so other methods to treat AML are highly requ...
Source: Colloids and Surfaces - June 6, 2022 Category: Biotechnology Authors: Eman M Hassan Shan Zou Source Type: research